Type I diabetes results from an autoimmune destruction of the insulin-producing pancreatic b cells. Although the exact immunologic processes underlying this disease are unclear, increasing evidence suggests that immunosuppressive, immunoregulatory and anti-inflammatory agents can interrupt the progression of the disease. Alpha 1 antitrypsin (AAT) is a multifunctional serine proteinase inhibitor (serpin) that also displays a wide range of anti-inflammatory properties. To test the ability of AAT to modulate the development of type I diabetes, we performed a series of investigations involving recombinant adeno-associated virus vector (rAAV)-mediated gene delivery of human alpha-1 antitrypsin (hAAT) to nonobese diabetic (NOD) mice. Recombinant AAV-expressing hAAT (rAAV2-CB-AT) was administered intramuscularly to 4-week-old female NOD mice (1 Â 10 10 i.u./mouse). A single injection of this vector reduced the intensity of insulitis, the levels of insulin autoantibodies, and the frequency of overt type I diabetes (30% (3/10) at 32 weeks of age versus 70% (7/10) in controls). Transgene expression at the injection sites was confirmed by immunostaining. Interestingly, antibodies against hAAT were present in a majority of the vector-injected mice and circulating hAAT was undetectable when assessed 10 weeks postinjection. This study suggests a potential therapeutic role for AAT in preventing type I diabetes as well as the ability of AAV gene therapy-based approaches to ameliorate disease effectively.
Introduction
The nonobese diabetic (NOD) mouse is a widely accepted model for investigating the pathogenesis of type I diabetes and to evaluate the effectiveness of interventions aimed at disease prevention. 1 In this model, a mononuclear cell infiltrate begins at 5 weeks of age within the pancreatic ducts and venules, and eventually progresses to the pancreatic islets (ie insulitis). This early stage of insulitis appears 'nondestructive' in terms of b-cell death, but as infiltration of the islets continues, destruction of the insulin-secreting b cells eventually occurs. The cellular infiltrate is heterogeneous, with a predominance of T cells followed by various percentages of macrophages, dendritic cells and B-lymphocytes. Multiple lines of evidence suggest that both CD4 þ T-helper and CD8 þ T-cytotoxic lymphocytes play a role in the formation of this disorder. [2] [3] [4] [5] [6] [7] The evidence for spontaneous b-cell regeneration is limited, and allogeneic islets transplanted into diabetic recipients typically are subjected to recurrence of autoimmune disease.
Alpha 1 antitrypsin (AAT) is a 52 kDa glycoprotein, which inhibits neutrophil elastase and proteinase 3 with high efficiency, and cathepsin G, thrombin, trypsin and chymotrypsin with lower efficiency. 8 AAT can inhibit alpha defensins and functions as an antioxidant. Under inflammatory conditions, AAT can also be chemically modified by nitric oxide (NO) and exhibit antibacterial and cysteine protease inhibitor activities. 9 AAT is primarily synthesized in the liver, but can also be produced by extrahepatic cells, including pancreatic islets, neutrophils, monocytes, macrophages, alveolar macrophages, intestinal epithelial cells, carcinoma cells and the cornea. [10] [11] [12] [13] [14] [15] Normal serum levels of AAT in humans are 11-30 mM (0.8-2.4 mg/ml). During inflammation, infection and malignant diseases, AAT levels, as an acute phase reactant, can rise by 3-to 4-fold. In human neutrophils, monocytes, alveolar macrophages and intestinal epithelial cells, AAT expression increases in response to inflammatory mediators such as lipopolysaccharide, TNFa, interleukin (IL)-1, IL-6, and the complex of AAT and neutrophil elastase. [16] [17] [18] [19] Increasing evidence indicates that the anti-inflammatory properties of AAT may allow for it to serve as a therapeutic agent for altering the immune response. For example, AAT delivery can completely abolish acute inflammatory infiltration and connective tissue breakdown. 20 Churg et al recently have demonstrated that human alpha-1 antitrypsin (hAAT) can suppress silicainduced PMN influx into the lung and macrophage inflammatory protein-2 (MIP-2) and monocyte chemotactic protein-1 (MCP-1) gene expression. 21 Human AAT also partially suppressed nuclear transcription factor-kB (NF-kB) translocation and increased the levels of inhibitor of NF-kB (I-kB). 21 It has also been demonstrated that adenovirus-mediated AAT gene transfer can significantly decrease neointimal formation after mechanical dilation, and reverses the local inflammation that characterizes viral controls. 22 Here, we report that hAAV-mediated AAT delivery to muscle interrupts the progression of autoimmune diabetes in NOD mice. This same vector has previously been shown to mediate high-level expression of hAAT in C57Bl/6 mice when injected either intramuscularly (i.m.) or into the portal vein. 23 These earlier studies indicated that hAAT expression was very long lived and that the vector-expressed hAAT had the same appearance as a native AAT on Western blot hybridization. 24 However, this is the first study to demonstrate biological activity of muscle-derived hAAT in a disease model. It further suggests a novel therapeutic approach for type I diabetes.
Results
To test the effect of hAAT in preventing type I diabetes, female NOD mice were injected i.m. with saline or saline containing recombinant adeno-associated virus vector (rAAV)2-CB-AT vector (1 Â 10 10 i.u./mouse, n¼10) at 4 weeks of age. Life table analysis (Figure 1) showed that a single injection of rAAV2-CB-AT vector prevented type I diabetes development (70% of treated animals were diabetes free at 32 weeks of age versus 30% of control animals, P¼0.02).
To understand the mechanism underlying this prevention, we performed a separate experiment in which control and vector injected (as described above) animals were killed at 16-20 weeks of age to monitor insulitis development. Semiquantitative scoring of multiple pancreatic sections obtained from all injected animals showed that the rAAV2-CB-AT-injected group had less severe insulitis (Figure 2 , 60 % islets remained intact, score of 0 or 1) than the control group (30% islets remained intact, score of 0 or 1). 25 The number of islets in the hAAT-treated group was also higher than in the control group (data not shown). These results indicate that systemic overexpression of AAT protects pancreatic islets against immunological destruction.
Insulin autoantibodies (IAAs) are one of the most commonly used indicators for predicting type I diabetes both in humans and more recently in NOD mice. They also serve as a marker of anti-b-cell immunity. In this study, we measured the serum IAA levels of all control and vector-injected animals. While not subject to statistical evaluation, IAA levels in vector-injected animals appeared to be lower than saline-injected animals as assessed by the number of animals that were IAA positive. These results suggest that hAAT gene transfer altered the humoral immune response associated with anti-b-cell immunity ( Figure 3 ).
To evaluate transgene expression over time, muscle tissue from injection sites was harvested at the time of killing and subjected to immunostaining for the analysis of hAAT expression. Human AAT in muscle fiber, as visualized by the use of rabbit anti-hAAT antibody, is demonstrated in Figure 4 . Human AAT was continuously expressed in the injection sites from 10 to 32 weeks of age (6-28 weeks postinjection). A key observation was that no inflammatory infiltration was observed at injection sites. Surprisingly, no hAAT was detected by ELISA in the serum of any vector-injected animals (tested at 10, 12, 14, 16 and 32 weeks of age, data not shown).
Since no hAAT was detected after injection of relatively high dose of rAAV2-CB-AT (1 Â 10 10 i.u.), we hypothesized that the NOD mouse may be immunosensitive to hAAT. To test this hypothesis, we performed ELISA to detect anti-hAAT antibodies. Figure 5 shows that hAAT gene transfer results in strong humoral immune response to hAAT in NOD mice. 10 i.u./mouse) or saline (this data was taken for comparison purpose from our previous paper. 25 We have performed IL-10 study and AAT study at the same time. Thus, the saline-injected group served as a control for both studies. Copyright 2001 National Academy of Sciences, USA). Alpha-1 antitrypsin gene therapy for type I diabetes S Song et al
Discussion
Previously, we have reported that rAAV-mediated gene delivery of the cytokine, IL-10 can completely prevent type I diabetes in NOD mice. 25 Results from this study showed that gene transfer of hAAT, a serine proteinase inhibitor, also prevented type I diabetes, suggesting that anti-inflammatory agents (cytokines and serpins) play important roles in regulating the immune system. The exact molecular and cellular mechanism(s) by which AAT prevents type I diabetes remain to be investigated. However, diminished insulitis scores and reduction of index values for IAA suggest that AAT therapy alters bcell-specific immunity. One possible mechanism is through the inhibition of a wide range of molecules (elastase, defensins, reactive oxygen species) released by leukocytes at the site of infiltration, resulting in the prevention of tissue damage. 20, 26, 27 Another possible mechanism is by the regulation of monocyte gene expression. The C-terminus of AAT can bind to cell surface receptors and act on various cell types. [28] [29] [30] [31] For example, AAT downregulates MIP-2 and MCP-1 gene expression. 21 It is likely that AAT can regulate cytokine expression and other immune effector molecules.
An important possibility that must be considered is that immunization against a foreign protein (hAAT) alone was responsible for all of the protective effects, rather than the biological activity of the AAT itself. In such a scenario, early immunization with a secreted protein might lead to a predominantly MHC class II context for the presentation of the antigen and subsequently elicit primarily a T-helper 2 response. Since the progression to diabetes depends upon a Th1 predominance, this early drive toward a Th2-predominant response could offer some protective effect. There are a variety of reasons why we feel that this is not the case. First, our group has carried out a series of other studies with rAAV2 vectors delivered i.m. in NOD mice. It is quite clear from studies with a null vector that immunization with rAAV2 capsid alone is not sufficient to protect NOD mice from developing diabetes. 32 Likewise, studies with a GFP-expressing vector have indicated that immunization against a foreign transgene product alone is not sufficient for protection in a transplantation model for type I diabetes. 33, 34 Only studies in which a biologically active molecule, like IL-10 is expressed from the rAAV vector have demonstrated the capability of preventing diabetes. 25 In these (b) IAA levels in saline-injected animals (this data was taken for comparison purpose from our previous paper. 25 We have performed IL-10 study and AAT study at the same time. Thus, the saline-injected group served as a control for both studies. Alpha-1 antitrypsin gene therapy for type I diabetes S Song et al cases, there is a direct correlation between the protective effect and the expression of the biologically active molecule, the expansion of a CD4 þ /CD25 þ pool and the expression of MHC class II on macrophages (data not shown). This suggests a very specific therapeutic effect on the prevention of Th1-predominant autoimmune responses. Future studies will focus on improving the degree of type I diabetes prevention afforded by hAAT gene therapy. This may be achieved by means of increasing transgene expression, including optimization of the vector dose, promoter and enhancer, and target tissue for gene delivery. In addition, complete prevention of diabetes may also be achieved by fine-tuning the timing of vector administration.
We have previously reported that rAAV2-mediated muscle and liver gene transfer result in 800-1000 mg/ml of hAAT in the serum of C57bl/6 mice. 24, 35 We have observed that strains of mice respond to hAAT gene transfer differently. 24 In C57BL/6 mice, rAAV-mediated hAAT gene transfer to either liver or muscle resulted in sustained high levels of hAAT in the circulation and generated no immune response to hAAT. In some Balb/c mice, AAT gene transfer to muscle generated strong immune responses to hAAT, resulting in little to no detectable AAT in the circulation. With a similar dose (1 Â 10 10 i.u./animal) of rAAV2 vector, we have now observed protective effects of hAAT in NOD mice and local transgene expression within the injected muscle mass. No free serum hAAT was detected. However, anti-AAT antibodies were generated in the NOD mice. This immune response seems restricted to humoral immunity, since no inflammation was observed at the injection site. These results are consistent with our recent observations that NOD mice are much more immunologically responsive to both AAV capsid components and transgene products (data not shown). The immune response to the transgene product might be avoided by utilizing mouse AAT in this model. However, there are seven copies of mouse alpha-1 proteinase inhibitor gene that have been cloned. 36 The identification of the functional equivalent or equivalents of AAT in mice remains to be investigated. In addition, in order to identify any potential substrain-specific phenotypes involved studies of hAAT in NOD mice, future studies should also be attempted in NOD. Jax mice (The Jackson Laboratory, Bar Harbor, Maine, USA).
One possibility, which could account for a protective effect without detectable hAAT in serum, is that the early expression of hAAT was sufficient for islet protection before high levels of antibody production, which normally takes 8-10 weeks. In related studies with IL-10 gene therapy, serum IL-10 could only be detected 2-4 weeks after vector injection, and yet major biological effects were observed. 25 Our ongoing studies showed i.m. injection of rAAV1-CB-AT resulted in high serum level (300 mg/ml) of hAAT in NOD mice, a level 2-3 logfold higher than observed with the same dose of rAAV2-CB-AT (data not shown). Although anit-hAAT antibodies were also detected in these mice, the serum levels of hAAT were sustained for at least 14 weeks after injection. Another possibility is that constitutively expressed AAT formed complexes with its antibody. These complexes might have remained functional in spite of their inability to be detected by ELISA. Supporting this possibility is the observations that AAT even when complexed with neutrophil elastase can interact with cells and regulate gene expression. 21, 28, 37 In summary, we have shown that rAAV2-mediated hAAT gene transfer to skeletal muscle prevents type I diabetes development in NOD mice. These results imply that hAAT has a therapeutic potential in the treatment of type I diabetes.
Materials and methods rAAV vector production and administration
A recombinant AAV2 vector (CB-AT)-containing hAAT cDNA driven by CMV enhancer and chicken b-actin promoter was constructed and packaged as described previously.
23 A 4-week-old female NOD.Martac mice (Taconic Farms) were injected in their hind limb musculature (one site with multiple directions per limb) with 100 ml of saline or saline-containing rAAV2-CB-AT (1 Â 10 10 i.u./animal). All animal manipulations were approved by the Institution Animal Care and Use Committees at the University of Florida.
Blood glucose monitoring and life table analysis
Blood glucose levels were monitored weekly. When the levels exceeded 240 mg/dl on two consecutive occasions (greater than 24 h apart), animals were considered type I diabetic and killed for pathological examinations.
Detection of IAAs
IAA were measured by RIA with radiolabeled insulin and protein A-Sepharose. 25 . Briefly, 125I-labelled insulin (Amersham, Piscataway, NJ, USA) was allowed to react with mouse sera and controls for 72 h at 41C. Immune complexes were then precipiatated with protein ASepharose (Zymed, San Francisco, CA, USA). The counts per minute (c.p.m.) were used to calculate an index relative to positive and negative controls. A cutoff index for positivity of 12.2 was used based on the mean index þ 3 s.d. of 30 C57BL/6 control mice. Weeks of age Alpha-1 antitrypsin gene therapy for type I diabetes S Song et al
Detection of hAAT 1and antibodies against hAAT
Serum hAAT levels were determined by ELISA as described previously. 23,24. For the detection of anti-hAAT antibodies, microtiter plates (Immoulon 4, Dynex Technologies, Chantilly, VA, USA) are coated with purified hAAT (1 mg/well, Sigma, Immunochemical, St Louis, MI, USA) in Voller's buffer overnight at 41C. After blocking with 3% bovine serum albumin, serially diluted unknown samples are incubated in the plate at 371C for 1 h. Goat anti-mouse IgG antibody (1:1500 diluted, Boehringer Mannheim, Germany) was reacted at 371C for 1 h. The plate is washed with PBS-Tween 20 between reactions. After reaction with the substrate (o-phenylenediamine, Sigma Immunochemical, St Louis, MI, USA) plates were read at 490 nm on an MRX microplate reader (Dynex Technologies, Chantilly, VA, USA).
Histopathology and immunohistochemistry
Saline-and vector-injected (at 4 weeks of age) animals were killed in experimental groups at 10-32 weeks of age or at the onset of diabetes. Representative pieces of heart, jejunum, kidney, liver, lung, salivary gland, lymph node and ovary were fixed in 10% neutral-buffered formalin and submitted for routine paraffin processing. Histopathological examination was performed on H&E sections. The injected muscle sites and equivalent untreated muscles were collected into 4% paraformaldehyde, embedded in paraffin, sectioned at 4 mm and stained with H&E. All slides were independently read and scored by two pathologists in a blinded fashion using a consistent and semiquantitative method based on the following scale for inflammatory infiltrates: 0¼none, 1¼focal, 2¼multifocal, mild; 3¼multifocal, moderate; and 4¼multifocal, severe.
The entire pancreas was harvested from each mouse and gently flattened in a cryomold containing a small amount of OCT-embedding media. The cryomold was filled with OCT then flash frozen in an isopentane bath at À601C (Histobath). The frozen blocks were stored at À701C until sectioning. The frozen pancreas was sectioned at 4 mm until the largest cut surface of the pancreas was represented. Frozen sections from each animal were stained with H&E for the assessment of insulitis. Insulitis was determined as reported previously. 25 The pancreas was examined using a Â 20 objective and each islet was graded according to the following scale: 0¼normal islet, 1¼peri-islet lymphocytic inflammation, 2¼o50% islet lymphocytic infiltration and 3¼450% islet lymphocytic infiltration. Additional pancreatic sections were immunostained with anti-insulin (1:200 DAKO) to determine b-cell functionality within the islets.
Immunostaining for human AAT was performed on both injected and untreated muscle. Sections (4 mm) were deparaffinized, rehydrated and then heated for 25 min at 951C in Trilogy Unmasking Solution (Cell Marque, Hot Springs, AR, USA). Rabbit anti-hAAT (Roche, Indianapolis, IN, USA) was applied to the slides at 1:2500 and detected using a commercially available alkaline phosphatase kit following the manufacturer's instructions (Rabbit ABC, Vector Laboratories, Burlingame, CA, USA). Vector Blue Substrate was the chosen for the chromagen with Nuclear Fast Red as the counterstain. Additional sections were stained as above using Rabbit IgG in place of the primary antibody. Slides were mounted with Aqua Seal (Care Express, Cary, IL, USA) and then photographed using an Olympus Provis microscope system equipped with a digital camera and MagnaFire software.
Statistical analysis
Survival curves were analyzed by life table analysis (Kaplan-Meier) using GraphPad Prizm software (GraphPad Software Inc., Santiago, CA, USA). Statistical significance is defined as Po0.05.
